Second- and third-generation ALK inhibitors for non-small cell lung cancer.

ABSTRACT: Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib. This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib.

SUBMITTER: Wu J 

PROVIDER: S-EPMC4782349 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature